ZIM Laboratories

ZIM Laboratories EPS

The Earnings per Share (EPS) of ZIM Laboratories (ZIMLAB.NS) as of Nov 21, 2026 is 1.09 INR. In the previous year, Earnings per Share (EPS) was 2.50 INR — a change of -56.32% (lower).

EPS

1.09INR

YoY

-56.32%

Last updated:

Earnings per Share (EPS) of ZIM Laboratories is 2026 1.09 INR. Earnings per Share (EPS) of ZIM Laboratories was 2025 2.50 INR. It decreases by -56.32% lower compared to the previous year.

The ZIM Laboratories EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2019
3.16 INR
Jan 1, 2020
0.68 INR
Jan 1, 2021
1.51 INR
Jan 1, 2022
2.98 INR
Jan 1, 2023
5.00 INR
Jan 1, 2024
3.53 INR
Jan 1, 2025
2.50 INR
Jan 1, 2026
1.09 INR
The ZIM Laboratories EPS history
YEAREPSYoY
1.09INR-56.32%
2.50INR-29.38%
3.53INR-29.37%
5.00INR+68.17%
2.98INR+97.18%
1.51INR+121.82%
0.68INR-78.46%
3.16INR-19.54%
3.93INR+2.73%
3.82INR+301.38%
0.95INR-123.59%
-4.04INR-313.08%
1.89INR+6.47%
1.78INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ZIM Laboratories Stock analysis

What does ZIM Laboratories do? Zim Laboratories Ltd. develops, manufactures, and supplies oral solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) across therapeutic segments including central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology, and vitamins, minerals, and dietary supplements. The company's technological capabilities focus on drug release modification, solubility and stability enhancement, taste masking, and dosage form transformation. Its product offerings include finished formulations such as tablets, capsules, oral thin films, granules, pellets, taste-masked powders, and dry suspensions, alongside pre-formulation intermediates. The firm generates revenue through the supply of these pharmaceutical products to healthcare providers and distributors within the Indian market. The company's delivery solutions encompass product conceptualization, development, registration filing, manufacturing, and supply, targeting various therapeutic segments. Its differentiated generic formulations cater to specific medical needs, with a focus on innovation in drug delivery systems. Zim Laboratories Ltd. serves the Indian pharmaceutical market, supplying both finished products and pre-formulation intermediates to meet the demands of healthcare institutions and retail pharmacies. Zim Laboratories Ltd. operates as a pharmaceutical company based in Nagpur, Maharashtra, with 525 full-time employees. It develops and manufactures generic pharmaceutical products including oral solid dosage forms and pre-formulation intermediates. The company's revenue streams come from the sale of these products to customers in the healthcare sector, particularly within the Indian market, leveraging its technological capabilities in drug formulation and delivery. ZIM Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ZIM Laboratories stock

Earnings per Share (EPS) of ZIM Laboratories is 1.09 INR in 2026.

Earnings per Share (EPS) of ZIM Laboratories changed from 2.50 INR to 1.09 INR, representing a -56.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) ZIM Laboratories since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ZIM Laboratories

All Key Metrics — ZIM Laboratories